✨ Free AI Report
ARS Pharmaceuticals, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research ARS Pharmaceuticals, Inc.
Company Research

ARS Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis

ARS Pharmaceuticals is a biopharmaceutical company focused on commercializing neffy, a needle-free intranasal epinephrine nasal spray for emergency treatment of Type I severe allergic reactions and anaphylaxis. The co...

Analyst-debate audio for ARS Pharmaceuticals, Inc.

AskCyborg analysts argue the bull and bear cases for ARS Pharmaceuticals, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
6/ 10Solid

Cyborg Score thesis

Growing revenue traction and regulatory wins support a turnaround narrative, but single-product dependency and valuation discount...

Read the full analyst-debate transcript →
Industry Biopharmaceutical - Specialty Pharma/Emergency Allergy Treatment
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest ARS Pharmaceuticals, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

ARS Pharmaceuticals, Inc. Overview

Pro stress-test →

ARS Pharmaceuticals is a biopharmaceutical company focused on commercializing neffy, a needle-free intranasal epinephrine nasal spray for emergency treatment of Type I severe allergic reactions and anaphylaxis. The company leverages its proprietary Intravail absorption enhancer technology to enable low-dose intranasal delivery, addressing a significant unmet need in emergency allergy care.

Strategic Profile

Pro stress-test →

ARS holds a competitive advantage through neffy's innovative delivery mechanism and expanding market access, including recent FDA approval and emerging pediatric and school-based penetration. The company is pursuing global expansion and new clinical indications, with recent regulatory approval in China demonstrating international traction and positioning for sustained revenue growth.

Competitive Landscape

Pro stress-test →

ARS operates in the epinephrine auto-injector and emergency allergy treatment market, competing primarily with established players like Mylan's EpiPen and newer alternatives. The company's competitive edge lies in neffy's needle-free intranasal delivery mechanism, which addresses patient hesitancy and safety concerns associated with traditional auto-injectors. Expanded pediatric access and payer coverage acceleration strengthen positioning against incumbents.

Industry Context

ARS Pharmaceuticals, Inc. operates in Biopharmaceutical - Specialty Pharma/Emergency Allergy Treatment.

Key facts

Founded: 2015 · Headquarters: San Diego, US · Revenue: $32.5M · Market cap: $923M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on ARS Pharmaceuticals, Inc..

  • Q3 2025 revenue of $32.5M exceeded analyst forecasts of $28.56M, demonstrating accelerating neffy market adoption
  • China's NMPA approval of neffy 2mg represents significant international expansion milestone beyond U.S. market
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 2026Zacks Research upgraded ARS from strong sell to hold rating amid improved fundamentals
  • December 2025China's NMPA approved neffy 2mg for emergency allergic reaction treatment
  • +2 moreTrack every material event for ARS Pharmaceuticals, Inc. as it happens. Explore monitoring →
Get alerted when ARS Pharmaceuticals, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

EpiPenInjectable epinephrine auto-injector (established market standard)→Auvi-QCompact auto-injector with voice guidance for anaphylaxis treatment→JextEuropean-focused epinephrine auto-injector alternative→

Compare ARS Pharmaceuticals, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

ARS Pharmaceuticals, Inc. operates in Biopharmaceutical - Specialty Pharma/Emergency Allergy Treatment. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical - Specialty Pharma/Emergency Allergy Treatment research →
NEW · MCP server

Ask your AI assistant about ARS Pharmaceuticals, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare ARS Pharmaceuticals, Inc. and its top competitor on Cyborg Score”
“What did ARS Pharmaceuticals, Inc. do this quarter?”
“Is ARS Pharmaceuticals, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does ARS Pharmaceuticals, Inc. do?+
ARS Pharmaceuticals is a biopharmaceutical company focused on commercializing neffy, a needle-free intranasal epinephrine nasal spray for emergency treatment of Type I severe allergic reactions and anaphylaxis. The co...
What is ARS Pharmaceuticals, Inc.'s Cyborg Score?+
ARS Pharmaceuticals, Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are ARS Pharmaceuticals, Inc.'s main competitors?+
Named competitors include EpiPen, Auvi-Q, Jext. The full competitive landscape is in the AskCyborg report.
How can I get the full ARS Pharmaceuticals, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the ARS Pharmaceuticals, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track ARS Pharmaceuticals, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.